Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.08
BSX's Cash to Debt is ranked lower than
94% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.24 vs. BSX: 0.08 )
Ranked among companies with meaningful Cash to Debt only.
BSX' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.13 Max: 0.69
Current: 0.08
0.03
0.69
Equity to Asset 0.35
BSX's Equity to Asset is ranked lower than
85% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. BSX: 0.35 )
Ranked among companies with meaningful Equity to Asset only.
BSX' s Equity to Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.5 Max: 0.63
Current: 0.35
0.18
0.63
F-Score: 6
Z-Score: 1.34
M-Score: -2.79
WACC vs ROIC
5.73%
-1.65%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -7.68
BSX's Operating margin (%) is ranked lower than
61% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. BSX: -7.68 )
Ranked among companies with meaningful Operating margin (%) only.
BSX' s Operating margin (%) Range Over the Past 10 Years
Min: -53.36  Med: -6.39 Max: 11.86
Current: -7.68
-53.36
11.86
Net-margin (%) -4.34
BSX's Net-margin (%) is ranked lower than
59% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 1.43 vs. BSX: -4.34 )
Ranked among companies with meaningful Net-margin (%) only.
BSX' s Net-margin (%) Range Over the Past 10 Years
Min: -56.12  Med: -9.22 Max: 5.79
Current: -4.34
-56.12
5.79
ROE (%) -5.39
BSX's ROE (%) is ranked lower than
58% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. BSX: -5.39 )
Ranked among companies with meaningful ROE (%) only.
BSX' s ROE (%) Range Over the Past 10 Years
Min: -44.65  Med: -5.9 Max: 3.89
Current: -5.39
-44.65
3.89
ROA (%) -1.94
BSX's ROA (%) is ranked lower than
54% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: -0.39 vs. BSX: -1.94 )
Ranked among companies with meaningful ROA (%) only.
BSX' s ROA (%) Range Over the Past 10 Years
Min: -21.16  Med: -2.76 Max: 2.03
Current: -1.94
-21.16
2.03
ROC (Joel Greenblatt) (%) -30.49
BSX's ROC (Joel Greenblatt) (%) is ranked lower than
60% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 4.23 vs. BSX: -30.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BSX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -153.31  Med: -20.85 Max: 32.39
Current: -30.49
-153.31
32.39
Revenue Growth (3Y)(%) 2.70
BSX's Revenue Growth (3Y)(%) is ranked lower than
54% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. BSX: 2.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BSX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.5  Med: 2.7 Max: 28.7
Current: 2.7
-10.5
28.7
EPS Growth (3Y)(%) -60.40
BSX's EPS Growth (3Y)(%) is ranked lower than
97% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. BSX: -60.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BSX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -60.4  Med: 7.2 Max: 62
Current: -60.4
-60.4
62
» BSX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

BSX Guru Trades in Q3 2015

Andreas Halvorsen 1,611,935 sh (New)
Alan Fournier 4,868,734 sh (+37.34%)
Vanguard Health Care Fund 64,108,690 sh (+7.52%)
Pioneer Investments 3,639,037 sh (+4.37%)
Diamond Hill Capital 20,724,859 sh (+2.51%)
Michael Price 1,980,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 43,608,364 sh (-5.40%)
Steven Cohen 2,638,300 sh (-5.45%)
Mario Gabelli 846,846 sh (-12.09%)
Ray Dalio 103,684 sh (-12.42%)
Dodge & Cox 472,960 sh (-19.60%)
» More
Q4 2015

BSX Guru Trades in Q4 2015

Jim Simons 3,471,705 sh (New)
Pioneer Investments 3,668,146 sh (+0.80%)
Vanguard Health Care Fund 64,108,690 sh (unchged)
Steven Cohen 650,000 sh (unchged)
Michael Price 1,980,000 sh (unchged)
Samuel Isaly 3,450,000 sh (unchged)
Andreas Halvorsen Sold Out
PRIMECAP Management 43,346,700 sh (-0.60%)
Mario Gabelli 821,746 sh (-2.96%)
Dodge & Cox 450,830 sh (-4.68%)
Diamond Hill Capital 19,599,806 sh (-5.43%)
Ray Dalio 88,284 sh (-14.85%)
Alan Fournier 3,909,834 sh (-19.70%)
Steven Cohen 690,300 sh (-73.84%)
» More
Q1 2016

BSX Guru Trades in Q1 2016

John Paulson 74,000 sh (New)
Steven Cohen 2,665,600 sh (+286.15%)
Diamond Hill Capital 20,339,317 sh (+3.77%)
Pioneer Investments 3,787,109 sh (+3.24%)
PRIMECAP Management 43,354,400 sh (+0.02%)
Samuel Isaly 3,450,000 sh (unchged)
Alan Fournier Sold Out
Vanguard Health Care Fund 63,222,390 sh (-1.38%)
Mario Gabelli 796,046 sh (-3.13%)
Dodge & Cox 427,430 sh (-5.19%)
Michael Price 1,740,000 sh (-12.12%)
Ray Dalio 36,184 sh (-59.01%)
Jim Simons 618,405 sh (-82.19%)
» More
Q2 2016

BSX Guru Trades in Q2 2016

Paul Tudor Jones 33,994 sh (New)
Jim Simons 4,901,905 sh (+692.67%)
John Paulson 94,000 sh (+27.03%)
Samuel Isaly 3,880,000 sh (+12.46%)
PRIMECAP Management 42,640,450 sh (-1.65%)
Dodge & Cox 384,930 sh (-9.94%)
Mario Gabelli 687,746 sh (-13.60%)
Vanguard Health Care Fund 53,619,190 sh (-15.19%)
Pioneer Investments 2,962,863 sh (-21.76%)
Steven Cohen 1,915,982 sh (-28.12%)
Michael Price 900,000 sh (-48.28%)
Ray Dalio 9,684 sh (-73.24%)
Diamond Hill Capital 4,863,821 sh (-76.09%)
» More
» Details

Insider Trades

Latest Guru Trades with BSX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NAS:ISRG, NYSE:ZBH, NYSE:EW, NYSE:STJ, NYSE:SYK, OTCPK:SNNUF, OTCPK:SONVY, NYSE:VAR, NYSE:TFX, NAS:ALGN, OTCPK:SDMHF, OTCPK:CHEOY, OTCPK:WILLF, NAS:ABMD, OTCPK:FSPKF, NAS:IART, OTCPK:EKTAF, OTCPK:GGNDF, NAS:NUVA, NAS:LIVN » details
Traded in other countries:BSX.Germany,
Boston Scientific Inc is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

Boston Scientific Corp is a developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. The Company's products were offered for sale by seven core businesses - Interventional Cardiology, Cardiac Rhythm Management (CRM), Endoscopy, Peripheral Interventions (PI), Urology and Women's Health, Neuromodulation, and Electrophysiology (EP). market a broad portfolio of internally-developed and self-manufactured drug-eluting stents including the Promus Element and Promus Element Plus everolimus-eluting stents, as well as its TAXUS Element and Ion paclitaxel-eluting stents. The Company sell various products designed to treat patients with peripheral disease (disease which appears in blood vessels other than in the heart and in the biliary tree), including a broad line of medical devices used in percutaneous transluminal angioplasty (PTA) and peripheral vascular stenting. Its peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. Its peripheral angioplasty balloon technology includes its next-generation Mustang PTA balloon, its Coyote balloon catheter, a deliverable and ultra-low profile balloon dilatation catheter designed for a wide range of peripheral angioplasty procedures, and its Charger PTA Balloon Catheter, a 0.035" percutaneous transluminal angioplasty balloon catheter designed for post-stent dilatation as well as conventional balloon angioplasty to open blocked peripheral arteries. The Company also sell products designed to treat patients with non-vascular disease (disease that appears outside the blood system). Its non-vascular suite of products includes biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The Company continue to market its extensive line of Interventional Oncology product solutions, including the recently launched Renegade HI-FLO Fathom microcatheter and guidewire system and Interlock - 35 Fibered IDC Occlusion System for peripheral embolization. The Company develop, manufacture and market a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including: Implantable cardioverter defibrillator (ICD), Implantable pacemaker systems. The Company is subject to various environmental laws, directives and regulations both in the U.S. and abroad. Its operations, like those of other medical device companies, involve the use of substances regulated under environmental laws in manufacturing and sterilization processes.

Ratios

vs
industry
vs
history
Forward P/E 22.78
BSX's Forward P/E is ranked higher than
61% of the 51 Companies
in the Global Medical Devices industry.

( Industry Median: 24.51 vs. BSX: 22.78 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 5.26
BSX's P/B is ranked lower than
70% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.93 vs. BSX: 5.26 )
Ranked among companies with meaningful P/B only.
BSX' s P/B Range Over the Past 10 Years
Min: 0.59  Med: 1.39 Max: 5.58
Current: 5.26
0.59
5.58
P/S 4.07
BSX's P/S is ranked lower than
61% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 3.21 vs. BSX: 4.07 )
Ranked among companies with meaningful P/S only.
BSX' s P/S Range Over the Past 10 Years
Min: 1.02  Med: 2.21 Max: 4.13
Current: 4.07
1.02
4.13
PFCF 33.20
BSX's PFCF is ranked lower than
66% of the 97 Companies
in the Global Medical Devices industry.

( Industry Median: 27.16 vs. BSX: 33.20 )
Ranked among companies with meaningful PFCF only.
BSX' s PFCF Range Over the Past 10 Years
Min: 7.26  Med: 20.45 Max: 220
Current: 33.2
7.26
220
POCF 25.54
BSX's POCF is ranked lower than
65% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. BSX: 25.54 )
Ranked among companies with meaningful POCF only.
BSX' s POCF Range Over the Past 10 Years
Min: 5.79  Med: 15.75 Max: 62.72
Current: 25.54
5.79
62.72
Current Ratio 1.05
BSX's Current Ratio is ranked lower than
88% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. BSX: 1.05 )
Ranked among companies with meaningful Current Ratio only.
BSX' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.5 Max: 3.46
Current: 1.05
0.52
3.46
Quick Ratio 0.74
BSX's Quick Ratio is ranked lower than
87% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. BSX: 0.74 )
Ranked among companies with meaningful Quick Ratio only.
BSX' s Quick Ratio Range Over the Past 10 Years
Min: 0.33  Med: 1.15 Max: 2.2
Current: 0.74
0.33
2.2
Days Inventory 159.35
BSX's Days Inventory is ranked lower than
62% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 133.25 vs. BSX: 159.35 )
Ranked among companies with meaningful Days Inventory only.
BSX' s Days Inventory Range Over the Past 10 Years
Min: 95.18  Med: 125.3 Max: 164.78
Current: 159.35
95.18
164.78
Days Sales Outstanding 63.63
BSX's Days Sales Outstanding is ranked higher than
57% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 68.90 vs. BSX: 63.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.51  Med: 61.98 Max: 66.79
Current: 63.63
58.51
66.79
Days Payable 44.60
BSX's Days Payable is ranked lower than
64% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 58.34 vs. BSX: 44.60 )
Ranked among companies with meaningful Days Payable only.
BSX' s Days Payable Range Over the Past 10 Years
Min: 21.66  Med: 35.22 Max: 340.03
Current: 44.6
21.66
340.03

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.20
BSX's 3-Year Average Share Buyback Ratio is ranked higher than
83% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. BSX: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BSX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.3  Med: -0.7 Max: 4.6
Current: 0.2
-22.3
4.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.68
BSX's Price/Projected FCF is ranked lower than
60% of the 128 Companies
in the Global Medical Devices industry.

( Industry Median: 2.12 vs. BSX: 2.68 )
Ranked among companies with meaningful Price/Projected FCF only.
BSX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.44 Max: 5.76
Current: 2.68
0.52
5.76
Price/Median PS Value 1.86
BSX's Price/Median PS Value is ranked lower than
83% of the 260 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. BSX: 1.86 )
Ranked among companies with meaningful Price/Median PS Value only.
BSX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.48  Med: 1.4 Max: 4.29
Current: 1.86
0.48
4.29
Price/Peter Lynch Fair Value 1.36
BSX's Price/Peter Lynch Fair Value is ranked lower than
99.99% of the 48 Companies
in the Global Medical Devices industry.

( Industry Median: 2.39 vs. BSX: 1.36 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BSX' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0  Med: 1.49 Max: 4.5
Current: 1.36
0
4.5
Earnings Yield (Greenblatt) (%) -1.70
BSX's Earnings Yield (Greenblatt) (%) is ranked lower than
55% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. BSX: -1.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BSX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.71  Med: 3.4 Max: 9.1
Current: -1.7
-1.71
9.1
Forward Rate of Return (Yacktman) (%) 42.24
BSX's Forward Rate of Return (Yacktman) (%) is ranked higher than
99% of the 117 Companies
in the Global Medical Devices industry.

( Industry Median: 7.47 vs. BSX: 42.24 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BSX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 3.1  Med: 7.1 Max: 43
Current: 42.24
3.1
43

More Statistics

Revenue (TTM) (Mil) $7,956
EPS (TTM) $ -0.26
Beta0.64
Short Percentage of Float1.61%
52-Week Range $14.18 - 24.79
Shares Outstanding (Mil)1,360.74

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 8,284 8,738 9,499
EPS ($) 1.06 1.18 1.44
EPS w/o NRI ($) 1.06 1.18 1.44
EPS Growth Rate
(3Y to 5Y Estimate)
15.60%
Dividends Per Share ($)
» More Articles for NYSE:BSX

Headlines

Articles On GuruFocus.com
Michael Price Trims Boston Scientific, Buys Outerwall Aug 23 2016 
Eaton Vance Worldwide Health Sciences Fund 2nd Quarter Commentary Aug 04 2016 
Vanguard Sold Shares in 7 of Top 10 Quarterly Transactions Aug 02 2016 
Sam Isaly's Top Investments of the Year Aug 01 2016 
Johnson & Johnson Reports 4% Sales Growth for the Second Quarter Jul 22 2016 
Weekly CEO Sells Highlight: Gilead Sciences, Boston Scientific, Sonic, HealthEquity Apr 10 2016 
Weekly CEO Sells Highlight: Motorcar Parts of America, The Interpublic Group of Companies, Gilead Sc Mar 07 2016 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Third Point's Third Quarter Letter Nov 02 2015 
Endo Pharmaceuticals Posts A Solid Q1 Earnings Report May 12 2015 

More From Other Websites
Analysts’ Latest Recommendations for Boston Scientific Aug 23 2016
Delving into BSX’s Category Leadership Growth Strategy Aug 22 2016
Zacks.com featured highlights: Macy's, Discovery Communications, Zoetis, Boston Scientific and... Aug 22 2016
What’s BSX’s Capital Allocation Strategy Going Forward? Aug 22 2016
Edwards Lifesciences Is Taking The Surgery Out Of Heart Surgery Aug 22 2016
Discussing Boston Scientific’s Expanding Operating Margins Aug 19 2016
What’s Driving Boston Scientific’s Rhythm Management Segment? Aug 19 2016
5 Top ROE Stocks to Play in an Aging Bull Market Aug 19 2016
How BSX Plans to Accelerate Its Neuromodulation Market Position Aug 18 2016
A Look at Boston Scientific’s Latest Valuation Aug 18 2016
FDA Approves Boston Scientific's Emblem MRI S-ICD System Aug 15 2016
BOSTON SCIENTIFIC CORP Financials Aug 10 2016
Boston Scientific Adds EMBLEM MRI S-ICD System To Its Growing ImageReady MR-Conditional Devices Aug 09 2016
Boston Scientific Announces U.S. FDA Approval Of EMBLEM™ MRI S-ICD System Aug 09 2016
Boston Scientific Announces U.S. FDA Approval Of EMBLEM™ MRI S-ICD System Aug 09 2016
[$$] Medicare Requires Some Heart Patients to See a Second Doctor Aug 08 2016
ETF’s with exposure to Boston Scientific Corp. : August 4, 2016 Aug 04 2016
Zacks.com featured highlights: Macy's, General Mills, Zoetis, Boston Scientific and Citrix Systems Aug 04 2016
BOSTON SCIENTIFIC CORP Files SEC form 10-Q, Quarterly Report Aug 03 2016
5 Top ROE Stocks to Buy as Earnings Growth Remains Elusive Aug 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)